Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Ofer Sharon"'
Autor:
David P Carbone, Jair Bar, Alona Zer, Yuval Shaked, Michal Harel, Coren Lahav, Eyal Jacob, Ofer Sharon, Nili Dahan, Itamar Sela, Yehonatan Elon, Galit Yahalom, Iris Kamer, Adam P Dicker, Shani Raveh Shoval
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/f1f33c7a45134017899795d4e2e594c1
Autor:
David Carbone, Jair Bar, Yuval Shaked, Michal Harel, Coren Lahav, Eyal Jacob, Adam Dicker, Ofer Sharon, Itamar Sela, Yehonatan Elon, Galit Yahalom, Iris Kamer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/bf502c926d9248b1889fa475138754af
Autor:
Mario Sznol, Ruth Halaban, Yuval Shaked, Michal Harel, Coren Lahav, Eyal Jacob, Eran Issler, Haim Bar, Adam Dicker, Ofer Sharon, Antonietta Bacchiocchi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/5b561c7de1df4983af5ef64e4da9a888
Autor:
Lori D. Bash, Dahlia Weitzman, Robert O. Blaustein, Ofer Sharon, Varda Shalev, Gabriel Chodick
Publikováno v:
Israel Journal of Health Policy Research, Vol 6, Iss 1, Pp 1-10 (2017)
Abstract Background Congestive heart failure (CHF) is among the most common causes of hospital admissions and readmissions in the Western world. However, the burden of ambulatory care has not been as well investigated. The objective of this study was
Externí odkaz:
https://doaj.org/article/88f76326f28744b5a288ac44f723bf66
Autor:
Yuval Shaked, Jair Bar, Michal Harel, Itamar Sela, Yehonatan Elon, Coren Lahav, Ofer Sharon, Eyal Jacob, Iris Kamer, Galit Yahalom, David P. Carbone, Adam P. Dicker
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by shifting the focus from the tumor to the immune system of the host. Despite durable response to ICIs, only a small proportion of non-small lung cancer (NSCLC) patie
Autor:
Michal Harel, Coren Lahav, Eyal Jacob, Nili Dahan, Itamar Sela, Yehonatan Elon, Shani Raveh Shoval, Galit Yahalom, Iris Kamer, Alona Zer, Ofer Sharon, David P Carbone, Adam P Dicker, Jair Bar, Yuval Shaked
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004582
BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized the cancer therapy landscape due to long-term benefits in patients with advanced metastatic disease. However, robust predictive biomarkers for response are still lacking and treatment
Autor:
Michal Harel, Yehonatan Elon, Hovav Nechushtan, Jair Bar, Itamar Sela, Alona Zer, Yuval Shaked, Maya Gottfried, M. Abu-Amana, Adam P. Dicker, Ofer Sharon, Rivka Katzenelson, Ido Wolf, Iris Kamer, Eyal Jacob, Abed Agbarya, Coren Lahav, Galit Yahalom, M.T. Moskovits
Publikováno v:
Annals of Oncology. 32:S388
Autor:
Alona Zer, Mor Moskovitz, Yuval Shaked, Maya Gottfried, Eyal Jacob, Yehonatan Elon, Mahmud Abu-Amana, Itamar Sela, Abed Agbarya, Jair Bar, Adam P. Dicker, Coren Lahav, Ofer Sharon, Rivka Katzenelson, Michal Harel, Ido Wolf, Hovav Nechushtan, Iris Kamer, Galit Yahalom, Haim Bar
Publikováno v:
Journal of Clinical Oncology. 39:e21110-e21110
e21110 Background: Immune checkpoint inhibitor (ICI) therapy represents one of the most promising cancer treatments to date. However, despite unprecedented rates of durable response, only a small proportion of patients benefits from this approach. Ma
Autor:
Ofer Sharon, Harvey L Katzeff, Kaan Tunceli, Samuel S. Engel, Noga Gadir, Larry Radican, Varda Shalev, Inbal Goldshtein, Shengsheng Yu, Avraham Karasik, Kimberly G. Brodovicz, Cheli Melzer-Cohen, Gabriel Chodick
Publikováno v:
Journal of Diabetes and its Complications. 30:1354-1359
Aim To compare the change in urinary albumin to creatinine ratio (UACR) in type 2 diabetes (T2DM) patients with albuminuria who initiate sitagliptin to those who initiate a sulfonylurea (SU) as add-on to metformin monotherapy. Method A cohort of T2DM
Autor:
Ofer Sharon, Coren Lahav, Haim Bar, Reema Jacob, Eyal Jacob, Ziv Raviv, Yuval Shaked, Adam P. Dicker, Avishag Shkedy, Eran Issler, Nili Dahan, Michal Harel, Irena Khononov, Ella Fremder
Publikováno v:
Cancer Research. 80:LB-401
Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm for non-small cell lung cancer (NSCLC) due to their unprecedented rates of durable response. However, their therapeutic efficacy is limited to a minority of NSCLC patients. Thus,